GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » Degree of Operating Leverage

STOK (Stoke Therapeutics) Degree of Operating Leverage : -0.06 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Stoke Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -0.06. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Stoke Therapeutics's Degree of Operating Leverage or its related term are showing as below:

STOK's Degree of Operating Leverage is ranked better than
52.67% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs STOK: -0.06

Stoke Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Stoke Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Degree of Operating Leverage Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial - - - -0.34 -0.04

Stoke Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 0.03 0.05 -0.04 -0.06

Competitive Comparison of Stoke Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Stoke Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stoke Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Stoke Therapeutics's Degree of Operating Leverage falls into.


;
;

Stoke Therapeutics Degree of Operating Leverage Calculation

Stoke Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 38.242 (Mar. 2025) / -118.454 (Mar. 2024) - 1 )/( 190.908 (Mar. 2025) / 7.845 (Mar. 2024) - 1 )
=-1.3228/23.335
=-0.06***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Stoke Therapeutics  (NAS:STOK) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Stoke Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Stoke Therapeutics Business Description

Traded in Other Exchanges
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Executives
Barry Ticho officer: Chief Medical Officer C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Jonathan Allan officer: General Counsel & Corp Sec C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Kaye Edward M. Md director, officer: CEO 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Skorpios Trust 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Huw M. Nash officer: COO & CBO C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Stephen J Tulipano officer: CFO C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Atp Life Science Ventures, L.p. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Montrago Trustees Ltd 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau officer: EVP Research & Preclinical Dev C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin director 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Arthur Tzianabos director C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730